Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · IEX Real-Time Price · USD
6.84
-0.13 (-1.87%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Adverum Biotechnologies Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for ADVM stock have an average target of 32.83, with a low estimate of 20 and a high estimate of 60. The average target predicts an increase of 379.97% from the current stock price of 6.84.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ADVM stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 3 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 1 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 4 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $25 | Buy | Initiates | $25 | +265.50% | Jun 25, 2024 |
| Truist Securities | Truist Securities | Strong Buy Maintains $60 | Strong Buy | Maintains | $60 | +777.19% | May 15, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $30 | Strong Buy | Reiterates | $30 | +338.60% | May 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +338.60% | Apr 30, 2024 |
| Mizuho | Mizuho | Strong Buy Maintains $40 → $22 | Strong Buy | Maintains | $40 → $22 | +221.64% | Apr 29, 2024 |
Financial Forecast
Revenue This Year
340.88K
from 3.60M
Decreased by -90.53%
Revenue Next Year
12.56M
from 340.88K
Increased by 3,585.71%
EPS This Year
-6.28
from -11.60
EPS Next Year
-6.12
from -6.28
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 1.8M | 63.0M | 63.0M | 75.6M | 63.0M |
| Avg | 340,884 | 12.6M | 20.9M | 16.4M | 38.5M |
| Low | n/a | n/a | n/a | n/a | 19.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -51.2% | 18,381.4% | 401.4% | 261.5% | 284.0% |
| Avg | -90.5% | 3,585.7% | 66.5% | -21.5% | 134.7% |
| Low | - | - | - | - | 19.5% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -5.47 | -4.49 | -4.43 | -4.08 | -2.32 |
| Avg | -6.28 | -6.12 | -5.69 | -5.48 | -3.87 |
| Low | -7.90 | -8.26 | -6.31 | -6.89 | -5.08 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.